SCOPUS 정보 검색 플랫폼

Journal of Clinical Pharmacology

Volumn 51, Issue 8, 2011, Pages 1233-1236

Pharmacokinetic interaction between zolpidem and carbamazepine in healthy volunteers

(6) Vlase, Laurian a Popa, Adina a Neag, Maria a Muntean, Dana b Bĝldea, Ioan b Leucuţa, Sorin E a

a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY (Romania)

b BABE BOLYAI UNIVERSITY (Romania)

Author keywords

carbamazepine; drug interaction; pharmacokinetics; Zolpidem

Indexed keywords

CARBAMAZEPINE; SANVAL; UNCLASSIFIED DRUG; ZOLPIDEM;

ADULT; AREA UNDER THE CURVE; ARTICLE; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INTERACTION; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NORMAL HUMAN; PHARMACOKINETICS; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUNTEER;

ADULT; ANTICONVULSANTS; BIOLOGICAL AVAILABILITY; CARBAMAZEPINE; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INDUCTION; GABA-A RECEPTOR AGONISTS; HALF-LIFE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; METABOLIC CLEARANCE RATE; PYRIDINES; YOUNG ADULT;

EID: 79960714888 PISSN: 00912700 EISSN: 15524604 Source Type: Journal
DOI: 10.1177/0091270010383690 Document Type: Article

Times cited : (25)

References (12)

1
- 0029074925
- Clinical pharmacokinetics and pharmacodynamics of zolpidem: Therapeutic implications
- Salvà P, Costa J. Clinical pharmacokinetics and pharmacodynamics of zolpidem: therapeutic implications. Clin Pharmacokinet. 1995 ; 29 (3). 142-153
- (1995) Clin Pharmacokinet , vol.29 , Issue.3 , pp. 142-153
- Salvà, P.¹ Costa, J.²

2
- 0032986686
- Zolpidem metabolism in vitro: Responsible cytochromes, chemical inhibitors, and in vivo correlations
- DOI 10.1046/j.1365-2125.1999.00953.x
- Von Moltke LL, Greenblatt DJ, Granda BW, et al. Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations. Br J Clin Pharmacol. 1999 ; 48: 89-97 (Pubitemid 29296668)
- (1999) British Journal of Clinical Pharmacology , vol.48 , Issue.1 , pp. 89-97
- Von Moltke, L.L.¹ Greenblatt, D.J.² Granda, B.W.³ Su Xiang Duan⁴ Grassi, J.M.⁵ Venkatakrishnan, K.⁶ Harmatz, J.S.⁷ Shader, R.I.⁸

3
- 12944331138
- Zolpidem: A review of its use in the management of insomnia
- DOI 10.2165/00023210-200519010-00008
- Harrison TS, Keating GM. Zolpidem: a review of its use in the management of insomnia. CNS Drugs. 2005 ; 19 (1). 65-89 (Pubitemid 40173974)
- (2005) CNS Drugs , vol.19 , Issue.1 , pp. 65-89
- Harrison, T.S.¹ Keating, G.M.²

4
- 67349106390
- Short-term clarithromycin administration impairs clearance and enhances pharmacodynamic effects of trazodone but not of zolpidem
- Farkas D, Volak LP, Harmatz JS, von Moltke LL, Court MH, Greenblatt DJ. Short-term clarithromycin administration impairs clearance and enhances pharmacodynamic effects of trazodone but not of zolpidem. Clin Pharmacol Ther. 2009 ; 85 (6). 644-650
- (2009) Clin Pharmacol Ther , vol.85 , Issue.6 , pp. 644-650
- Farkas, D.¹ Volak, L.P.² Harmatz, J.S.³ Von Moltke, L.L.⁴ Court, M.H.⁵ Greenblatt, D.J.⁶

5
- 84857119938
- Ambiem (zolpidem tartrat) tablets CIV [prescribing information]. Accessed April 20
- Ambiem (zolpidem tartrat) tablets CIV [prescribing information]. http://products.sanofi-aventis.us/ambien/ambien.pdf. Accessed April 20, 2010.
- (2010)

6
- 33845408447
- Effect of voriconazole on the pharmacokinetics and pharmacodynamics of zolpidem in healthy subjects
- Saari TI, Laine K, Leino K, Valtonen M, Neuvonen PJ, Olkkola KT. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of zolpidem in healthy subjects. Br J Clin Pharmacol. 2006 ; 63 (1). 116-120
- (2006) Br J Clin Pharmacol , vol.63 , Issue.1 , pp. 116-120
- Saari, T.I.¹ Laine, K.² Leino, K.³ Valtonen, M.⁴ Neuvonen, P.J.⁵ Olkkola, K.T.⁶

7
- 34250630391
- Pharmacokinetic and pharmacodynamic interactions between zolpidem and caffeine
- DOI 10.1038/sj.clpt.6100211, PII 6100211
- Cysneiros RM, Farkas D, Harmatz JS, von Moltke LL, Greenblatt DJ. Pharmacokinetic and pharmacodynamic interactions between zolpidem and caffeine. Clin Pharmacol Ther. 2007 ; 82 (1). 54-62 (Pubitemid 46944198)
- (2007) Clinical Pharmacology and Therapeutics , vol.82 , Issue.1 , pp. 54-62
- Cysneiros, R.M.¹ Farkas, D.² Harmatz, J.S.³ Von Moltke, L.L.⁴ Greenblatt, D.J.⁵

8
- 0031417357
- Rifampin reduces plasma concentrations and effects of zolpidem
- DOI 10.1016/S0009-9236(97)90082-5
- Villikka K, Kivistö KT, Luurila H, Neuvonen PJ. Rifampin reduces plasma concentrations and effects of zolpidem. Clin Pharmacol Ther. 1997 ; 62 (6). 629-634 (Pubitemid 28068066)
- (1997) Clinical Pharmacology and Therapeutics , vol.62 , Issue.6 , pp. 629-634
- Villikka, K.¹ Kivisto, K.T.² Luurila, H.³ Neuvonen, P.J.⁴

9
- 0038714895
- Clinically important drug interactions in epilepsy: Interactions between antiepileptic drugs and other drugs
- DOI 10.1016/S1474-4422(03)00483-6
- Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol. 2003 ; 2 (8). 473-481 (Pubitemid 36876104)
- (2003) Lancet Neurology , vol.2 , Issue.8 , pp. 473-481
- Patsalos, P.N.¹ Perucca, E.²

10
- 0032977818
- Clinically significant pharmacokinetic drug interactions between antiepileptic drugs
- Tanaka E. Clinically significant pharmacokinetic drug interactions between antiepileptic drugs. J Clin Pharm Ther. 2002 ; 24 (2). 87-92
- (2002) J Clin Pharm Ther , vol.24 , Issue.2 , pp. 87-92
- Tanaka, E.¹

11
- 0037131879
- Genetic contribution to variable human CYP3A-mediated metabolism
- DOI 10.1016/S0169-409X(02)00066-2, PII S0169409X02000662
- Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev. 2002 ; 54: 1271-1294 (Pubitemid 35284253)
- (2002) Advanced Drug Delivery Reviews , vol.54 , Issue.10 , pp. 1271-1294
- Lamba, J.K.¹ Lin, Y.S.² Schuetz, E.G.³ Thummel, K.E.⁴

12
- 73849111326
- Cytochrome P450 proteins: Retention and distribution from the endoplasmic reticulum
- Neve EPA, Ingelman-Sundberg M. Cytochrome P450 proteins: retention and distribution from the endoplasmic reticulum. Curr Opin Drug Discov Dev. 2010 ; 13 (1). 78-85
- (2010) Curr Opin Drug Discov Dev , vol.13 , Issue.1 , pp. 78-85
- Epa, N.¹ Ingelman-Sundberg, M.²

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.